Home > Boards > US OTC > Delisted > Intellicell Biosciences, Inc. (fka SVFC)

SVFC : In-Human Clinical Studies

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (11) | Next 10 | Previous | Next
lee13 Member Profile
 
Followed By 36
Posts 3,727
Boards Moderated 0
Alias Born 10/02/12
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
lee13   Friday, 12/13/13 05:18:57 PM
Re: None
Post # of 91005 
SVFC : In-Human Clinical Studies

Osteoarthritis - phase 1 and 2a study

Dr. James Andrews & Prof. Saith Jazrawi (NYU), Dr. John Theodopolous (Mt. Sinai Toronto)
Focus: pain relief and cartilage regeneration using SVF via intravenous and injection. Randomized double-blind dose-controlled study to show safety and primary efficacy

Multiple Sclerosis - phase 1 and 2a study

Dr. Fred Lublim (Mt. Sinai, NY) recipient of largest-ever NIH grant ($40M) to find MS cure
In planning stages with Dr. Lublim for open label study of moderate to severe MS patients

Non-Healing Diabetic Ulcers - phase 1 and 2a study

Dr. Harold Brem (Winthrop Univ. Hospital NY), one of the foremost wound healing authorities
IntelliCell and Dr. Brem are developing a treatment methodology that may substantially alter
outcomes for subjects facing amputation as the only alternative

Oral Cavity Gum and Bone Regeneration - phase 1 and 2a study

Dr. Nicholas Toscano, Manhattan periodontics specialist
Study based on peer-reviewed SVF article showing restoration of gum tissue and bone mass

Dermal Regeneration - phase 1 and 2a study

Dr. Sydney Coleman (NY) and Dr. Peter Ashby (London), expert plastic surgeon in autologous cellular treatments
Study will focus on the regenerative capability of IntelliCells to address the aesthetic effects of SVF on wrinkles, lines, scarring, and burn conditions in the human skin

CORPORATE COLLABORATIONS

Millipore, a Division of Merck, Germany
accumulation of data and QA of specimens using flow cytometry

Numoda Corporation, Philadelphia
clinical trial accounting as our Clinical Research Organization



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (11) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences